Legendary Trader: “Buy These Three Stocks Before this September Event”

Luke Lango believes an event scheduled for mid-September is set to trigger a massive market shock, potentially defining the winners and losers for the rest of the year.  

Wed, September 11 at 8:00PM ET
 
 
 
 
Register Here
Healthcare Stocks Icon

Healthcare Stocks

Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.

The words "recession proof" written on a pink sticky note. bulletproof stocks

7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024

These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.

Interest rate and dividend concept. Businessman with percentage symbol and up arrow, Interest rates continue to increase, return on stocks and mutual funds, long term investment for retirement. Dividend stocks

7 Dependable Dividend Stocks for Long-Term Income

Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.

medicine research, pharmaceutical background, LJPC stock

3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct

These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.

Other industries you might be interested in

Icon depicting a DNA strand

Biotech

Marijuana leaf

Cannabis

Icon depicting pills

Psychedelics

Recent Healthcare Stocks Articles

Why Is Azitra (AZTR) Stock Down 70% Today?

By William White, InvestorPlace Writer
Azitra stock is falling on Wednesday after the company announced the pricing and other details from a public offering for AZTR shares.

Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report

By Samuel O'Brient, InvestorPlace Reporter
Kerrisdale Capital has released a short report, making clear why it is betting against ALT stock. Here's why Altimmune is likely in trouble.

7 High-Yield Dividend Stocks for the Ultimate Retirement Portfolio

By Yiannis Zourmpanos, InvestorPlace Contributor
Retirement planning is a vital phase of life (the climax) that demands careful strategic investment decisions.

3 Blue-Chip Stocks Drowning in Earnings Despair

By Joel Baglole, InvestorPlace Contributor
Investors should shy away from these companies after they delivered substandard financial results for the final months of last year.

Why Is G1 Therapeutics (GTHX) Stock Down 45% Today?

By William White, InvestorPlace Writer
G1 Therapeutics stock is down on Tuesday after the company provided GTHX investors with an update on a Phase 3 clinical trial.

The 3 Best Biotech Stocks to Buy in February 2024

By Viktor Zarev, InvestorPlace Contributor
The best biotech stocks to buy offer consistent growth opportunities and resist the influence of singular drug successes.

3 Gene Editing Stocks With Unprecedented Surge Potential

By Ian Cooper, InvestorPlace Contributor
While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential.

Get Rich Quick With These 3 Penny Stocks to Buy Now

By Michael Que, InvestorPlace Contributor
Our economy has and will continue to show strength and resilience, you should invest in these three penny stocks to buy quick.

Why Is MindMed (MNMD) Stock Up 8% Today?

By Samuel O'Brient, InvestorPlace Reporter
MindMed and other psychedelic stocks are rising today on news of an FDA priority review. Here's what this means for MNMD stock and its peers.

3 Growth Stocks to Sell in February Before They Bottom

By Yiannis Zourmpanos, InvestorPlace Contributor
Discover why these growth stocks to sell are facing adversities in automotive retail, aerospace, defense and biotechnology.

T2 Biosystems Receives 510(K) Clearance for Its Bacteria Panel

By Eddie Pan, InvestorPlace Financial News Writer
TTOO stock is in the green after the company received FDA approval for an additional bacteria on its T2Bacteria Panel.

Why is CymaBay (CBAY) Stock Up 25% Today?

By William White, InvestorPlace Writer
CymaBay stock is rising higher on Monday as CBAY investors react to a $4.3 billion acquisition deal with Gilead Sciences.

The 3 Most Undervalued Small-Cap Stocks to Buy in February 2024

By Gabriel Osorio-Mazzilli, InvestorPlace Contributor
Small-cap stocks are the first ones to rally on a new business cycle, such as the business cycle starting recently.

Why Is Intelligent Bio Solutions (INBS) Stock Down 24% Today?

By William White, InvestorPlace Writer
Intelligent Bio Solutions stock is falling on Monday as shares of INBS give up some of the gains they saw on Friday after releasing earnings.

7 Dividend Stocks to Buy at a 52-Week Low 

By Chris Markoch, InvestorPlace Contributor
Each of these dividend stocks has been down sharply in the last 12 months but has fundamental reasons that support a turnaround.

7 Stocks That Could Plummet if the Fed Leaves Rates Too High for Too Long

By Thomas Niel, InvestorPlace Contributor
As the Fed could take a prudent approach to rate cuts, these are the seven stocks to sell before interest rates fall.

Passive Income Powerhouses: 7 Blue-Chip Stocks to Own Now

By Vandita Jadeja
If you are looking to build wealth through dividend income, here are the passive income blue-chip stocks to buy.

3 Doomed Biotech Stocks to Dump Before They Dive: February 2024

By Muslim Farooque, InvestorPlace Contributor
Spot the looming risks in the biotech sector and avoid these three doomed biotech stocks likely to burn shareholder value significantly.

3 Themes That Will Dominate the Stock Market This Year

By Jeremy Flint, InvestorPlace Contributor
These stock market trends are already showing themselves to be driving market discussion for 2024, and it's still early.
Load More Articles